ONUREG

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug ONUREG contains one active pharmaceutical ingredient (API):

1	Azacitidine UNII M801H13NRU - AZACITIDINE
	Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways.
	Read more about Azacitidine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ONUREG Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC07	Azacitidine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1852275, 1852286, 1852297, 1852309
FR	Base de données publique des médicaments	64799168, 67694966
IL	מִשְׂרַד הַבְּרִיאוּת	9047, 9048
IT	Agenzia del Farmaco	049620014, 049620026, 049620038, 049620040
LT	Valstybinė vaistų kontrolės tarnyba	1092904, 1092905, 1092906, 1092907
PL	Rejestru Produktów Leczniczych	100455330, 100455348
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67898001, W67899001
US	FDA, National Drug Code	59572-730, 59572-740